Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.

中文翻译：

---

PSMA Theranostics：当前状态和未来方向。

前列腺特异性膜抗原（PSMA）是前列腺癌及其转移的影像学诊断和靶向放射性核素治疗（热疗）的有前途的目标。越来越多的证据表明，使用177Lu标记的PSMA配体可提高转移率，去势抵抗性前列腺癌的放射配体疗法（RLT）的应答率和低毒性。在本文中，我们回顾了使用放射性标记的PSMA配体的诊断和治疗的当前状态。我们还建议用于患者选择标准和基于PSMA的RLT行为的方案。讨论了PSMA治疗学的挑战和机遇。